Prevalence of insulin resistance and prediction of glucose intolerance and type 2 diabetes mellitus in women with polycystic ovary syndrome

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 5, 2007, Pages 639-644

  Vrbikova, Jana ^a   Dvorakova, Katerina ^a   Grimmichova, Tereza ^a   Hill, Martin ^a   Stanicka, Sona ^a   Cibula, David ^b   Bendlova, Bela ^a   Starka, Luboslav ^a   Vondra, Karel ^a  

^a INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Diabetes mellitus type 2; Homeostatic model assessment of insulin resistance (HOMA IR); Impaired glucose tolerance; Polycystic ovary syndrome

Indexed keywords

CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CHEMICAL PARAMETERS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; SCREENING; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; MASS SCREENING; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE OF TESTS; PREVALENCE; SENSITIVITY AND SPECIFICITY;

EID: 34248199400     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.113     Document Type: Article

References (31)

1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
2. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004;59:141-54.
3. Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet 2001;75:177-84.
4. Vrbikova J, Cifkova R, Jirkovska A, Lanska V, Platilova H, Zamrazil V, et al. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod 2003;18:980-4.
5. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9.
6. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-6.
7. Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin-dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000;15:785-9.
8. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005;90:4650-8.
9. Borch-Johnsen K. IGT and IFG. Time for revision? Diabet Med 2002;19:707.
10. The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-21.
11. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-7.
12. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
13. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
14. Mohlig M, Floter A, Spranger J, Weickert MO, Schill T, Schlosser HW, et al. Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling. Diabetologia 2006;49:2572-9.
15. Mohlig M, Spranger J, Ristow M, Pfeiffer AF, Schill T, Schlosser HW, et al. Predictors of abnormal glucose metabolism in women with polycystic ovary syndrome. Eur J Endocrinol 2006;154:295-301.
16. The Rotterdam ESHRE-FASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
17. Hampl R. Comparison of three immunoassays for testosterone determination. In: Görög S, editor. Advances in steroid analysis 93. Budapest: Akadémiai Kiadó, 1994: 163-9.
18. Putz Z, Hampl R, Vanuga A, Veleminsky J, Starka L. A selective radioimmunoassay of androstenedione in plasma and saliva. J Clin Chem Clin Biochem 1982;20:761-4.
19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
20. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
22. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10.
23. Deugarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005;83:1454-60.
24. Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004;82:661-5.
25. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. Br J Obstet Gynaecol 2006;113:1210-7.
26. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006;91:4237-45.
27. Acien P, Quereda F, Matallin P, Villarroya E, Lopez-Fernandez JA, Acien M, et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999;72:32-40.
28. American Diabetes Association. Consensus Development Conference on Insulin Resistance. Nov 5-6, 1997. Diabetes Care 1998;21:310-4.
29. Larsson H, Lindgarde F, Berglund G, Ahren B. Prediction of diabetes using ADA or WHO criteria in post-menopausal women: a 10-year follow-up study. Diabetologia 2000;43:1224-8.
30. Kim SH, Abbasi F, Reaven GM. Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care 2004;27:1998-2002.
31. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002;25:2016-21.